Tevogen Bio Holdings Inc. secures up to $50 million in financing with a $36 million line of credit and a $14 million private placement. The funding will support research and development, focusing on TVGN 489 and strengthening their IP portfolio with 3 US patents and 21 pending international patents. The private placement option is available at a 30% discount to the 10-day average share price of $10. Tevogen is focused on developing off-the-shelf T cell therapies for infectious diseases, cancers, and neurological disorders, with a commitment to patient accessibility and innovative business models.

Read more at GlobeNewswire: REPEAT — Tevogen Bio Enters Into Agreement for Up to $50